Dutasteride reduces incident prostate cancer in men after negative prostate biopsy

Evidence-Based Medicine

Volumn 15, Issue 4, 2010, Pages 119-120

  Vickers, Andrew ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO;

CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL TRIAL; HUMAN; MALE; NOTE; PROSTATE BIOPSY; PROSTATE CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 77955239458     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1082     Document Type: Note

References (6)

1. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20:680-8.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61. (Pubitemid 351439226)
4. Thompson IM, Goodman PJ, Tangen CM, et al. The infl uence of fi nasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
5. Vickers AJ, Savage CJ, Lilja H. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol 2010;28:1112-16.
6. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006;175:505-9. (Pubitemid 43067339)